DOCSLIB.ORG

Functional Study of Transcriptional Corepressor GPS2 and Tumor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Functional Study of Transcriptional Corepressor GPS2 and Tumor THE FUNCTIONAL STUDY OF TRANSCRIPTIONAL COREPRESSOR G- PROTEIN SUPRESSOR 2 (GPS2) AND TUMOR SUPRESSOR PROMYELOCYTIC LEUKEMIA (PML) by XIWEN CHENG Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Advisor: Dr. Hung-Ying Kao Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY August, 2010 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of __Xiwen Cheng__________________ candidate for the Ph.D. degree*. (signed)_______David_Samols__Ph.D._________________ (chair of the committee) _____________Edward Stavnezer__Ph.D._____________ _____________Gary Landreth___Ph.D.________________ _____________Hung-Ying Kao___Ph.D.________________ _____________Youwei Zhang____Ph.D._______________ ________________________________________________ (date) __May 26, 2010____________ *We also certify that written approval has been obtained for any proprietary material contained therein. To my parents and family Table of Contents LIST OF TABLES ................................................................................................. 7 LIST OF FIGURES ............................................................................................... 8 ACKNOWLEDGEMENTS ................................................................................... 12 LIST OF ABBREVIATIONS ................................................................................ 13 CHAPTER 1: INTRODUCTION ...................................................................... 19 Transcription: a central mechanism to maintain the normality of life.................................................................................................................... 19 Nuclear receptors (NRs): a family of sensors to hormonal signaling .......................................................................................................... 21 Transcription cofactors: coactivators and corepressors .................................. 22 SMRT corepressor complexes and GPS2 ....................................................... 25 The identification of GPS2 ............................................................................... 27 GPS2 interacts with many cellular proteins ..................................................... 28 The biological functions of GPS2 .................................................................... 29 The structure, motif and signature sequence of GPS2 protein ........................ 34 Estrogen receptor and breast cancers ............................................................ 35 The tamoxifen-resistant breast cancers .......................................................... 37 Acute promyelocytic leukemia (APL) ............................................................... 38 The promyelocytic leukemia protein (PML) ..................................................... 41 PML nuclear bodies......................................................................................... 42 PML: an emerging tumor suppressor .............................................................. 43 PML plays a role in endothelial physiology ...................................................... 43 1 PML is induced by inflammation ...................................................................... 44 Angiogenesis, tumor growth and inflammation ................................................ 45 The controversy of TNFα in tumor therapy ...................................................... 46 Microarray is a powerful tool to identify alterations of expression of genes at genomic scale ............................................................................... 50 CHAPTER 2: G-PROTEIN PATHWAY SUPRESSOR 2 (GPS2), AN INTEGRAL COMPONENT OF THE SMRT COMPLEXES, IS IMPORTANT FOR ESTROGEN RECEPTOR ALPHA (ERα)- MEDIATED TRANSCRIPTIONAL REGULATION AND CELL PROLIFERATION ............................................................................................... 54 ABSTRACT ..................................................................................................... 54 INTRODUCTON .............................................................................................. 55 MEATERIALS AND METHODS ...................................................................... 58 Reagents, plasmids, and antibodies ............................................................ 58 Affinity Antibody purification ......................................................................... 59 Yeast two-hybrid screens ............................................................................. 60 GST pull-down assays ................................................................................. 60 Co-immunoprecipitation of transfected protein ............................................ 61 Histone deacetylase assays ........................................................................ 62 Fluorescence microscopy ............................................................................ 62 Subcellular fractionation ............................................................................... 63 Quantitative reverse transcription PCR (qRT-PCR) ..................................... 63 Transient transfection of siRNA ................................................................... 64 2 Luciferase reporter assays ........................................................................... 64 Chromatin immunoprecipitaion (ChIP) assays ............................................. 65 RESULTS ........................................................................................................ 69 Isolation of GPS2 as a SMRT-interaction protein by Yeast two- hybrid (Y2H). ................................................................................................ 69 GPS2 binds to SMRT in vivo and in vitro ..................................................... 69 GPS2 associates with histone deacetylases. ............................................... 71 GPS2 is a transcriptional corepressor. ......................................................... 71 GPS2 associates with ERα target gene promoter in a ligand- dependent manner ....................................................................................... 73 Knockdown of GPS2 altered the expression of ERα target genes. .......................................................................................................... 74 Knockdown of GPS2 altered the pattern of recruitment of SMRT corepressor complex components .................................................... 75 GPS2 and SMRT suppress breast cancer cell proliferation. ........................ 77 DISCUSSION ................................................................................................ 101 Biological significance of the study ............................................................ 101 The role of GPS2 in transcriptional regulation. .......................................... 102 The role of GPS2 in ERα-mediated transcription. ...................................... 103 Recruitment of corepressors to ERα target gene promoter. ....................... 105 The role of corepressor complex in breast cancers. .................................. 105 CHAPTER 3: PROMYELOCYTIC LEUKEMIA PROTEIN (PML) REGULATES ENDOTHELIAL CELL NETWORK FORMATION 3 AND MIGRATION IN RESPONSE TO TUMOR NECROSIS FACTOR ALPHA (TNFα) AND INTERFERON ALPHA (IFNα) ......................... 109 ABSTRACT ................................................................................................... 109 INTRODUCTION ........................................................................................... 110 MATERIALS AND METHODS ...................................................................... 113 Reagents and Antibodies ........................................................................... 113 Cell culture, Drug treatment and siRNA transfection .................................. 114 Total RNA extraction, RT-PCR and Real-time PCR ................................... 114 Immunofluorescence microscopy............................................................... 115 Promoter analysis ...................................................................................... 115 Chromatin immunoprecipitaion (ChIP) assays ........................................... 116 In vitro angiogenesis assay ........................................................................ 117 In vitro wound-healing assay ..................................................................... 117 Western blotting and quantification of band intensity ................................. 118 RESULTS ...................................................................................................... 119 DISCUSSION ................................................................................................ 140 CHAPTER 4: MICROARRAY ANALYSIS OF THE TRANSCRIPTOME FROM ENDOTHELIAL CELLS FOLLOWING PML KNOCKDOWN ......................................................................................... 146 ABSTRACT ................................................................................................... 146 INTRODUCTION ........................................................................................... 147 MATERIALS AND METHODS ...................................................................... 152 Sample preparation and the arrays ............................................................ 152 4 Data preprocessing ...................................................................................
Load more

Recommended publications
  • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
    Published OnlineFirst October 26, 2016; DOI: 10.1158/2159-8290.CD-15-1263 RESEARCH ARTICLE The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer Jennifer L. Bishop1, Daksh Thaper1,2, Sepideh Vahid1,2, Alastair Davies1, Kirsi Ketola1, Hidetoshi Kuruma1, Randy Jama1, Ka Mun Nip1,2, Arkhjamil Angeles1, Fraser Johnson1, Alexander W. Wyatt1,2, Ladan Fazli1,2, Martin E. Gleave1,2, Dong Lin1, Mark A. Rubin3, Colin C. Collins1,2, Yuzhuo Wang1,2, Himisha Beltran3, and Amina Zoubeidi1,2 ABSTRACT Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mecha- nistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with clas- sic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. SIGNIFICANCE: Understanding the contribution of the AR to the emergence of highly lethal, drug- resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design.
    [Show full text]
  • Core Transcriptional Regulatory Circuitries in Cancer
    Oncogene (2020) 39:6633–6646 https://doi.org/10.1038/s41388-020-01459-w REVIEW ARTICLE Core transcriptional regulatory circuitries in cancer 1 1,2,3 1 2 1,4,5 Ye Chen ● Liang Xu ● Ruby Yu-Tong Lin ● Markus Müschen ● H. Phillip Koeffler Received: 14 June 2020 / Revised: 30 August 2020 / Accepted: 4 September 2020 / Published online: 17 September 2020 © The Author(s) 2020. This article is published with open access Abstract Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type- specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics. 1234567890();,: 1234567890();,: Introduction genes. Till now, one critical goal in biology remains to understand the composition and hierarchy of transcriptional Transcriptional regulation is one of the fundamental mole- regulatory network in each specified cell type/lineage.
    [Show full text]
  • Viral Resistance and IFN Signaling in STAT2 Knockout Fish Cells Carola E
    Viral Resistance and IFN Signaling in STAT2 Knockout Fish Cells Carola E. Dehler, Katherine Lester, Giulia Della Pelle, Luc Jouneau, Armel Houel, Catherine Collins, Tatiana Dovgan, This information is current as Radek Machat, Jun Zou, Pierre Boudinot, Samuel A. M. of September 26, 2021. Martin and Bertrand Collet J Immunol published online 29 May 2019 http://www.jimmunol.org/content/early/2019/05/28/jimmun ol.1801376 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/05/28/jimmunol.180137 Material 6.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published May 29, 2019, doi:10.4049/jimmunol.1801376 The Journal of Immunology Viral Resistance and IFN Signaling in STAT2 Knockout Fish Cells Carola E. Dehler,* Katherine Lester,† Giulia Della Pelle,‡ Luc Jouneau,‡ Armel Houel,‡ Catherine Collins,† Tatiana Dovgan,*,† Radek Machat,‡,1 Jun Zou,*,2 Pierre Boudinot,‡ Samuel A.
    [Show full text]
  • A Molecular Switch from STAT2-IRF9 to ISGF3 Underlies Interferon-Induced Gene Transcription
    ARTICLE https://doi.org/10.1038/s41467-019-10970-y OPEN A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription Ekaterini Platanitis 1, Duygu Demiroz1,5, Anja Schneller1,5, Katrin Fischer1, Christophe Capelle1, Markus Hartl 1, Thomas Gossenreiter 1, Mathias Müller2, Maria Novatchkova3,4 & Thomas Decker 1 Cells maintain the balance between homeostasis and inflammation by adapting and inte- grating the activity of intracellular signaling cascades, including the JAK-STAT pathway. Our 1234567890():,; understanding of how a tailored switch from homeostasis to a strong receptor-dependent response is coordinated remains limited. Here, we use an integrated transcriptomic and proteomic approach to analyze transcription-factor binding, gene expression and in vivo proximity-dependent labelling of proteins in living cells under homeostatic and interferon (IFN)-induced conditions. We show that interferons (IFN) switch murine macrophages from resting-state to induced gene expression by alternating subunits of transcription factor ISGF3. Whereas preformed STAT2-IRF9 complexes control basal expression of IFN-induced genes (ISG), both type I IFN and IFN-γ cause promoter binding of a complete ISGF3 complex containing STAT1, STAT2 and IRF9. In contrast to the dogmatic view of ISGF3 formation in the cytoplasm, our results suggest a model wherein the assembly of the ISGF3 complex occurs on DNA. 1 Max Perutz Labs (MPL), University of Vienna, Vienna 1030, Austria. 2 Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna 1210, Austria. 3 Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria. 4 Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna 1030, Austria.
    [Show full text]
  • PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain
    Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 RESEARCH ARTICLE PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability Berkley E. Gryder 1 , Marielle E. Yohe 1 , 2 , Hsien-Chao Chou 1 , Xiaohu Zhang 3 , Joana Marques 4 , Marco Wachtel4 , Beat Schaefer 4 , Nirmalya Sen 1 , Young Song 1 , Alberto Gualtieri 5 , Silvia Pomella 5 , Rossella Rota5 , Abigail Cleveland 1 , Xinyu Wen 1 , Sivasish Sindiri 1 , Jun S. Wei 1 , Frederic G. Barr 6 , Sudipto Das7 , Thorkell Andresson 7 , Rajarshi Guha 3 , Madhu Lal-Nag 3 , Marc Ferrer 3 , Jack F. Shern 1 , 2 , Keji Zhao8 , Craig J. Thomas 3 , and Javed Khan 1 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2017 American Association for Cancer Research. 16-CD-16-1297_p884-899.indd 884 7/20/17 2:21 PM Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 ABSTRACT Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and ado- lescent young adults, driven primarily by the chimeric transcription factor PAX3–FOXO1. The mechanisms by which PAX3–FOXO1 dysregulates chromatin are unknown. We fi nd PAX3–FOXO1 repro- grams the cis -regulatory landscape by inducing de novo super enhancers. PAX3–FOXO1 uses super enhancers to set up autoregulatory loops in collaboration with the master transcription factors MYOG, MYOD, and MYCN. This myogenic super enhancer circuitry is consistent across cell lines and primary tumors. Cells harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced by, or bound to, PAX3–FOXO1-occupied super enhancers.
    [Show full text]
  • PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1
    Published OnlineFirst November 18, 2016; DOI: 10.1158/0008-5472.CAN-16-1546 Cancer Therapeutics, Targets, and Chemical Biology Research PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1 Abstract Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric PAX3-FOXO1A. Mechanistic investigations revealed a requirement disease driven by expression of the oncogenic fusion gene PAX3- for the NR4A1/Sp4 complex to bind GC-rich promoter regions FOXO1A. In this study, we report overexpression of the nuclear to elevate transcription of the PAX3-FOXO1A gene. In parallel, receptor NR4A1 in rhabdomyosarcomas that is sufficient to NR4A1 also regulated expression of b1-integrin, which with PAX3- drive high expression of PAX3-FOXO1A there. RNAi-mediated FOXO1A, contributed to tumor cell migration that was blocked by silencing of NR4A1 decreased expression of PAX3-FOXO1A and C-DIM/NR4A1 antagonists. Taken together, our results provide a its downstream effector genes. Similarly, cell treatment with the preclinical rationale for the use of NR4A1 small-molecule antago- NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p- nists to treat ARMS and other rhabdomyosarcomas driven by hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A. Cancer Res; 77(3); 1–10. Ó2016 AACR. Introduction activity for NR4A1. In contrast, NR4A1 exhibits tumor promoter activity (6, 7) in solid tumors. NR4A1 is also overexpressed in Rhabdomyosarcoma is the most common soft-tissue sarco- tumors from patients with breast, lung, pancreatic, colon, and ma that is primarily observed in children and adolescents and ovarian cancer and is a negative prognostic factor for patients with accounts for 50% of all pediatric cancers and 50% of soft-tissue breast, lung, and ovarian cancer (9–15).
    [Show full text]
  • Involvement of Corepressor Complex Subunit GPS2 in Transcriptional Pathways Governing Human Bile Acid Biosynthesis
    Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis Sabyasachi Sanyal*†, Ann Båvner‡, Anna Haroniti§, Lisa-Mari Nilsson¶, Thomas Lunda˚ senʈ, Stefan Rehnmark‡, Michael Robin Witt‡, Curt Einarsson¶, Iannis Talianidis§, Jan-Åke Gustafsson*, and Eckardt Treuter*† *Department of Biosciences and Nutrition, Karolinska Institutet, ‡Karo Bio AB, ¶Department of Gastroenterology and Hepatology, and ʈDepartment of Endocrinology, Metabolism, and Diabetes, Karolinska University Hospital, S-14157 Huddinge, Sweden; and §Biomedical Sciences Research Center, Alexander Fleming, 16672 Vari, Athens, Greece Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved August 16, 2007 (received for review July 18, 2007) Coordinated regulation of bile acid biosynthesis, the predominant histone methyltransferase (G9a) (ref. 15 and references therein). pathway for hepatic cholesterol catabolism, is mediated by few Here we identify GPS2 (G protein pathway suppressor 2), a key nuclear receptors including the orphan receptors liver receptor subunit of the NR corepressor (N-CoR) complex (16–18), as a homolog 1 (LRH-1), hepatocyte nuclear factor 4␣ (HNF4␣), small SHP cofactor that, by means of additional interactions with heterodimer partner (SHP), and the bile acid receptor FXR (farne- LRH-1, HNF4␣, and FXR, participates in the differential reg- soid X receptor). Activation of FXR initiates a feedback regulatory ulation of CYP7A1 and CYP8B1 expression in human liver cell loop via induction of SHP, which suppresses LRH-1- and HNF4␣- lines and primary human hepatocytes. Additionally, we provide dependent expression of cholesterol 7␣ hydroxylase (CYP7A1) and insights into the species- and gene-specific regulations of these sterol 12␣ hydroxylase (CYP8B1), the two major pathway enzymes.
    [Show full text]
  • Mutation and Expression Analysis in Medulloblastoma Yields Prognostic
    Bien-Willner and Mitra Acta Neuropathologica Communications 2014, 2:74 http://www.actaneurocomms.org/content/2/1/74 RESEARCH Open Access Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors Gabriel A Bien-Willner1,2* and Robi D Mitra2 Abstract Current consensus identifies four molecular subtypes of medulloblastoma (MB): WNT, sonic hedgehog (SHH), and groups “3/C” and “4/D”. Group 4 is not well characterized, but harbors the most frequently observed chromosomal abnormality in MB, i17q, whose presence may confer a worse outcome. Recent publications have identified mutations in chromatin remodeling genes that may be overrepresented in this group, suggesting a biological role for these genes in i17q. This work seeks to explore the pathology that underlies i17q in MB. Specifically, we examine the prognostic significance of the previously-identified gene mutations in an independent set of MBs as well as to examine biological relevance of these genes and related pathways by gene expression profiling. The previously-implicated p53 signaling pathway is also examined as a putative driver of i17q tumor oncogenesis. The data show gene mutations associated with i17q tumors in previous studies (KMD6A, ZMYM3, MLL3 and GPS2) were correlated with significantly worse outcomes despite not being specific to i17q in this set. Expression of these genes did not appear to underlie the biology of the molecular variants. TP53 expression was significantly reduced in i17q/ group 4 tumors; this could not be accounted for by dosage effects alone. Expression of regulators and mediators of p53 signaling were significantly altered in i17q tumors.
    [Show full text]
  • Role of Perforin-2 in Regulating Type I Interferon Signaling
    https://www.scientificarchives.com/journal/journal-of-cellular-immunology Journal of Cellular Immunology Review Article Role of Perforin-2 in Regulating Type I Interferon Signaling Gregory V Plano, Noula Shembade* Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center Miller School of Medicine, University of Miami, Miami, FL 33136, USA *Correspondence should be addressed to Noula Shembade; [email protected] Received date: November 21, 2020, Accepted date: February 02, 2021 Copyright: © 2021 Plano G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Sepsis is a systemic inflammatory response caused by a harmful host immune reaction that is activated in response to microbial infections. Infection-induced type I interferons (IFNs) play critical roles during septic shock. Type I IFNs initiate their biological effects by binding to their transmembrane interferon receptors and initiating the phosphorylation and activation of tyrosine kinases TYK2 and JAK1, which promote phosphorylation and activation of STAT molecules. Type I IFN-induced activation of JAK/STAT pathways is a complex process and not well understood. Improper regulation of type I IFN responses can lead to the development of infectious and inflammation-related diseases, including septic shock, autoimmune diseases, and inflammatory syndromes. This review is mainly focused on the possible mechanistic roles of the transmembrane Perforin-2 molecule in the regulation of type I IFN- induced signaling. Keywords: JAK/STAT, Interferons, TYK2, STATs, Perforin-2, IFNAR1, IFNAR2 and Signaling Introduction and activator of transcription 2), respectively, under normal physiological conditions [4,5].
    [Show full text]
  • Identification of Differentially Expressed Genes in Human Breast
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 2), pp: 2475-2501 Research Paper Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms Qi Fang1, Shuang Yao2, Guanghua Luo2 and Xiaoying Zhang2 1Department of Breast Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China 2Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China Correspondence to: Xiaoying Zhang, email: [email protected] Guanghua Luo, email: [email protected] Keywords: breast cancer; MCF-7; 4-hydroxyl tamoxifen; STAT1; STAT2 Received: June 05, 2017 Accepted: December 13, 2017 Published: December 20, 2017 Copyright: Fang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT While tamoxifen (TAM) is used for treating estrogen receptor (ER)a-positive breast cancer patients, its anti-breast cancer mechanisms are not completely elucidated. This study aimed to examine effects of 4-hydroxyltamoxifen (4-OH- TAM) on ER-positive (ER+) breast cancer MCF-7 cell growth and gene expression profiles. MCF-7 cell growth was inhibited by 4-OH-TAM dose-dependently with IC50 of 29 μM. 332 genes were up-regulated while 320 genes were down-regulated. The mRNA levels of up-regulated genes including STAT1, STAT2, EIF2AK2, TGM2, DDX58, PARP9, SASH1, RBL2 and USP18 as well as down-regulated genes including CCDN1, S100A9, S100A8, ANXA1 and PGR were confirmed by quantitative real-time PCR (qRT- PCR).
    [Show full text]
  • Vs. BCR-ABL-Positive Cells to Interferon Alpha
    Schubert et al. Journal of Hematology & Oncology (2019) 12:36 https://doi.org/10.1186/s13045-019-0722-9 RESEARCH Open Access Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL- positive cells to interferon alpha Claudia Schubert1, Manuel Allhoff2, Stefan Tillmann1, Tiago Maié2, Ivan G. Costa2, Daniel B. Lipka3, Mirle Schemionek1, Kristina Feldberg1, Julian Baumeister1, Tim H. Brümmendorf1, Nicolas Chatain1† and Steffen Koschmieder1*† Abstract Background: Interferon alpha (IFNa) monotherapy is recommended as the standard therapy in polycythemia vera (PV) but not in chronic myeloid leukemia (CML). Here, we investigated the mechanisms of IFNa efficacy in JAK2V617F- vs. BCR-ABL-positive cells. Methods: Gene expression microarrays and RT-qPCR of PV vs. CML patient PBMCs and CD34+ cells and of the murine cell line 32D expressing JAK2V617F or BCR-ABL were used to analyze and compare interferon-stimulated gene (ISG) expression. Furthermore, using CRISPR/Cas9n technology, targeted disruption of STAT1 or STAT2, respectively, was performed in 32D-BCR-ABL and 32D-JAK2V617F cells to evaluate the role of these transcription factors for IFNa efficacy. The knockout cell lines were reconstituted with STAT1, STAT2, STAT1Y701F, or STAT2Y689F to analyze the importance of wild-type and phosphomutant STATs for the IFNa response. ChIP-seq and ChIP were performed to correlate histone marks with ISG expression. Results: Microarray analysis and RT-qPCR revealed significant upregulation of ISGs in 32D-JAK2V617F but downregulation in 32D-BCR-ABL cells, and these effects were reversed by tyrosine kinase inhibitor (TKI) treatment. Similar expression patterns were confirmed in human cell lines, primary PV and CML patient PBMCs and CD34+ cells, demonstrating that these effects are operational in patients.
    [Show full text]
  • PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1
    Published OnlineFirst November 18, 2016; DOI: 10.1158/0008-5472.CAN-16-1546 Cancer Therapeutics, Targets, and Chemical Biology Research PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1 Abstract Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric PAX3-FOXO1A. Mechanistic investigations revealed a requirement disease driven by expression of the oncogenic fusion gene PAX3- for the NR4A1/Sp4 complex to bind GC-rich promoter regions FOXO1A. In this study, we report overexpression of the nuclear to elevate transcription of the PAX3-FOXO1A gene. In parallel, receptor NR4A1 in rhabdomyosarcomas that is sufficient to NR4A1 also regulated expression of b1-integrin, which with PAX3- drive high expression of PAX3-FOXO1A there. RNAi-mediated FOXO1A, contributed to tumor cell migration that was blocked by silencing of NR4A1 decreased expression of PAX3-FOXO1A and C-DIM/NR4A1 antagonists. Taken together, our results provide a its downstream effector genes. Similarly, cell treatment with the preclinical rationale for the use of NR4A1 small-molecule antago- NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p- nists to treat ARMS and other rhabdomyosarcomas driven by hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A. Cancer Res; 77(3); 1–10. Ó2016 AACR. Introduction activity for NR4A1. In contrast, NR4A1 exhibits tumor promoter activity (6, 7) in solid tumors. NR4A1 is also overexpressed in Rhabdomyosarcoma is the most common soft-tissue sarco- tumors from patients with breast, lung, pancreatic, colon, and ma that is primarily observed in children and adolescents and ovarian cancer and is a negative prognostic factor for patients with accounts for 50% of all pediatric cancers and 50% of soft-tissue breast, lung, and ovarian cancer (9–15).
    [Show full text]